image
Healthcare - Medical - Devices - NASDAQ - US
$ 17.25
1.47 %
$ 253 M
Market Cap
-2.6
P/E
1. INTRINSIC VALUE

Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management product family consists of Monovisc, Orthovisc, Cingal, and Hyvisc that are indicated to provide pain relief from osteoarthritis conditions; and joint preservation and restoration product family comprise a portfolio of approximately 150 bone preserving joint technology products, a line of sports medicine soft tissue repair solutions, and orthopedic regenerative solutions products.[ Read More ]

The intrinsic value of one ANIK stock under the base case scenario is HIDDEN Compared to the current market price of 17.2 USD, Anika Therapeutics, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart ANIK

image
FINANCIALS
167 M REVENUE
6.67%
-87.6 M OPERATING INCOME
-351.75%
-82.7 M NET INCOME
-456.34%
-1.79 M OPERATING CASH FLOW
-40.55%
-5.43 M INVESTING CASH FLOW
27.50%
-6.32 M FINANCING CASH FLOW
-30.34%
38.8 M REVENUE
-7.56%
-28 M OPERATING INCOME
-17401.86%
-29.9 M NET INCOME
-33897.73%
5.02 M OPERATING CASH FLOW
569.22%
-1.82 M INVESTING CASH FLOW
46.64%
-3.99 M FINANCING CASH FLOW
-259.23%
Balance Sheet Decomposition Anika Therapeutics, Inc.
image
Current Assets 163 M
Cash & Short-Term Investments 72.9 M
Receivables 36 M
Other Current Assets 54.5 M
Non-Current Assets 107 M
Long-Term Investments 0
PP&E 75 M
Other Non-Current Assets 32.4 M
Current Liabilities 31.1 M
Accounts Payable 9.86 M
Short-Term Debt 2.13 M
Other Current Liabilities 19.1 M
Non-Current Liabilities 27.3 M
Long-Term Debt 26.9 M
Other Non-Current Liabilities 404 K
EFFICIENCY
Earnings Waterfall Anika Therapeutics, Inc.
image
Revenue 167 M
Cost Of Revenue 63.6 M
Gross Profit 103 M
Operating Expenses 191 M
Operating Income -87.6 M
Other Expenses -4.97 M
Net Income -82.7 M
RATIOS
61.85% GROSS MARGIN
61.85%
-52.58% OPERATING MARGIN
-52.58%
-49.60% NET MARGIN
-49.60%
-38.95% ROE
-38.95%
-30.55% ROA
-30.55%
-40.00% ROIC
-40.00%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Anika Therapeutics, Inc.
image
Net Income -82.7 M
Depreciation & Amortization 14.2 M
Capital Expenditures -5.43 M
Stock-Based Compensation 15.2 M
Change in Working Capital -12.1 M
Others 70.5 M
Free Cash Flow -7.22 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Anika Therapeutics, Inc.
image
ANIK has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
0.00% DIVIDEND YIELD
0 USD DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership Anika Therapeutics, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
Date Value Insider Amount Avg Price
2 years ago
May 11, 2022
Bought 32.1 K USD
Colleran David
EVP, General Counsel, Corp Sec
+ 1500
21.37 USD
2 years ago
Mar 14, 2022
Bought 40 K USD
Colleran David
EVP, General Counsel, Corp Sec
+ 1500
26.652 USD
2 years ago
Mar 11, 2022
Bought 49.3 K USD
Thompson Jeffery S
director:
+ 2000
24.659 USD
2 years ago
Mar 11, 2022
Bought 98.4 K USD
Blanchard Cheryl R
President, CEO, Director
+ 3813
25.814 USD
2 years ago
Mar 11, 2022
Bought 109 K USD
Blanchard Cheryl R
President, CEO, Director
+ 4287
25.359 USD
2 years ago
Mar 11, 2022
Bought 98.5 K USD
Levitz Michael L
EVP, CFO, Treasurer
+ 4000
24.619 USD
3 years ago
Aug 12, 2021
Bought 31.2 K USD
Levitz Michael L
EVP, CFO, Treasurer
+ 777
40.205 USD
3 years ago
Aug 11, 2021
Bought 115 K USD
Levitz Michael L
EVP, CFO, Treasurer
+ 2850
40.206 USD
3 years ago
May 18, 2021
Bought 85.7 K USD
HENNEMAN JOHN B III
Director
+ 2000
42.86 USD
3 years ago
May 12, 2021
Sell 85.2 K USD
LAND RAYMOND J
Director
- 2000
42.6 USD
4 years ago
Nov 10, 2020
Sell 127 K USD
LAND RAYMOND J
Director
- 3446
36.77 USD
4 years ago
Jul 09, 2020
Sell 43.7 K USD
Loerop James
EVP Business Development
- 1244
35.15 USD
4 years ago
Feb 26, 2020
Sell 115 K USD
LAND RAYMOND J
Director
- 2700
42.68 USD
5 years ago
Nov 08, 2019
Sell 1.19 M USD
Cheung Sylvia
Chief Financial Officer
- 20000
59.71 USD
5 years ago
Aug 28, 2019
Sell 249 K USD
Larsen Glenn R.
Director
- 4355
57.21 USD
5 years ago
Aug 20, 2019
Sell 111 K USD
Bower Joseph L.
Director
- 1994
55.57 USD
5 years ago
Aug 08, 2019
Sell 274 K USD
Thompson Jeffery S
Director
- 4843
56.66 USD
5 years ago
Jul 29, 2019
Sell 166 K USD
LAND RAYMOND J
Director
- 3000
55.44 USD
5 years ago
Feb 28, 2019
Bought 33.2 K USD
Darling Joseph G
President and CEO; Director
+ 1000
33.2 USD
5 years ago
Feb 26, 2019
Sell 132 K USD
LAND RAYMOND J
Director
- 4000
33.06 USD
6 years ago
Nov 30, 2017
Sell 286 K USD
Hague Richard
Chief Commercial Officer
- 5250
54.48 USD
7 years ago
Oct 24, 2017
Sell 197 K USD
SHERWOOD CHARLES H
CEO and Director
- 3278
60.04 USD
7 years ago
Oct 20, 2017
Sell 360 K USD
SHERWOOD CHARLES H
CEO and Director
- 5991
60.04 USD
7 years ago
Oct 23, 2017
Sell 1.34 M USD
SHERWOOD CHARLES H
CEO and Director
- 22228
60.06 USD
7 years ago
Oct 16, 2017
Sell 198 K USD
SHERWOOD CHARLES H
CEO and Director
- 3293
60.04 USD
7 years ago
Oct 12, 2017
Sell 114 K USD
SHERWOOD CHARLES H
CEO and Director
- 1908
60 USD
7 years ago
Oct 13, 2017
Sell 314 K USD
SHERWOOD CHARLES H
CEO and Director
- 5216
60.11 USD
7 years ago
Jul 27, 2017
Sell 3.24 M USD
SHERWOOD CHARLES H
CEO and Director
- 63799
50.79 USD
7 years ago
Jul 03, 2017
Sell 298 K USD
SHERWOOD CHARLES H
President, CEO, Director
- 5965
50 USD
7 years ago
Jul 05, 2017
Sell 412 K USD
SHERWOOD CHARLES H
President, CEO, Director
- 8236
50.06 USD
7 years ago
May 19, 2017
Sell 52.2 K USD
Thompson Jeffery S
Director
- 1097
47.58 USD
7 years ago
May 22, 2017
Sell 456 K USD
Thompson Jeffery S
Director
- 9628
47.37 USD
7 years ago
Feb 24, 2017
Sell 31.7 K USD
Ahn Edward S.
Chief Tech & Strategy Officer
- 640
49.47 USD
7 years ago
Feb 22, 2017
Sell 129 K USD
LAND RAYMOND J
Director
- 2635
49.08 USD
7 years ago
Feb 22, 2017
Sell 58.5 K USD
Cheung Sylvia
Chief Financial Officer
- 1193
49.05 USD
7 years ago
Feb 22, 2017
Sell 39.6 K USD
Cheung Sylvia
Chief Financial Officer
- 807
49.02 USD
7 years ago
Feb 22, 2017
Sell 98 K USD
Cheung Sylvia
Chief Financial Officer
- 2000
49.01 USD
8 years ago
Nov 09, 2016
Sell 21.7 K USD
BOWER JOSEPH I
Director
- 500
43.4 USD
8 years ago
Nov 09, 2016
Sell 1.73 K USD
BOWER JOSEPH I
Director
- 40
43.31 USD
8 years ago
Feb 25, 2016
Sell 118 K USD
LAND RAYMOND J
Director
- 2695
43.62 USD
9 years ago
Aug 07, 2015
Sell 72.4 K USD
Moran John C
Director
- 2000
36.18 USD
9 years ago
Jul 30, 2015
Sell 25.8 K USD
LAND RAYMOND J
Director
- 690
37.39 USD
9 years ago
Jul 31, 2015
Sell 38.4 K USD
LAND RAYMOND J
Director
- 1018
37.76 USD
9 years ago
May 27, 2015
Sell 82.5 K USD
Moran John C
Director
- 2500
33 USD
9 years ago
Feb 26, 2015
Sell 99 K USD
Moran John C
Director
- 2500
39.61 USD
9 years ago
Feb 27, 2015
Sell 182 K USD
LAND RAYMOND J
Director
- 4621
39.49 USD
10 years ago
May 30, 2014
Sell 96.8 K USD
Moran John C
Director
- 2000
48.41 USD
10 years ago
Jan 27, 2014
Sell 474 K USD
Thompson Jeffery S
Director
- 10346
45.82 USD
10 years ago
May 01, 2014
Sell 3.71 M USD
SHERWOOD CHARLES H
President and CEO
- 83780
44.32 USD
10 years ago
Feb 27, 2014
Sell 2.18 M USD
SHERWOOD CHARLES H
President and CEO
- 50000
43.53 USD
10 years ago
Feb 28, 2014
Sell 6.16 M USD
SHERWOOD CHARLES H
President and CEO
- 150000
41.09 USD
10 years ago
Feb 27, 2014
Sell 387 K USD
LAND RAYMOND J
Director
- 8914
43.47 USD
11 years ago
Aug 22, 2013
Sell 122 K USD
Moran John C
Director
- 5000
24.35 USD
11 years ago
Aug 08, 2013
Sell 637 K USD
WHEELER STEVE E
Director
- 26984
23.61 USD
11 years ago
Aug 06, 2013
Sell 31.1 M USD
Fidia Farmaceutici S.p.A.
10 percent owner
- 1270000
24.52 USD
11 years ago
Aug 06, 2013
Sell 31.1 M USD
Fidia Farmaceutici S.p.A.
10 percent owner
- 1270000
24.52 USD
11 years ago
Aug 06, 2013
Sell 270 K USD
WHEELER STEVE E
Director
- 9918
27.23 USD
11 years ago
Aug 07, 2013
Sell 27.4 K USD
WHEELER STEVE E
Director
- 1098
24.99 USD
11 years ago
Jul 12, 2013
Sell 1.29 M USD
SHERWOOD CHARLES H
President and CEO
- 64544
20.03 USD
11 years ago
Jul 15, 2013
Sell 216 K USD
SHERWOOD CHARLES H
President and CEO
- 10456
20.63 USD
11 years ago
Jul 09, 2013
Sell 23.9 K USD
SHERWOOD CHARLES H
President and CEO
- 1321
18.11 USD
11 years ago
Jul 08, 2013
Sell 864 K USD
SHERWOOD CHARLES H
President and CEO
- 47864
18.06 USD
11 years ago
Jul 05, 2013
Sell 381 K USD
SHERWOOD CHARLES H
President and CEO
- 21157
18.01 USD
11 years ago
Jun 19, 2013
Sell 33.2 K USD
SHERWOOD CHARLES H
President and CEO
- 1847
18 USD
11 years ago
Mar 27, 2013
Sell 207 K USD
QUINLAN KEVIN W
Chief Financial Officer
- 18374
11.24 USD
11 years ago
Mar 22, 2013
Sell 225 K USD
QUINLAN KEVIN W
Chief Financial Officer
- 19998
11.24 USD
11 years ago
Mar 12, 2013
Sell 4.55 K USD
LAND RAYMOND J
Director
- 325
14 USD
11 years ago
Mar 12, 2013
Sell 13.3 K USD
LAND RAYMOND J
Director
- 950
14 USD
11 years ago
Mar 12, 2013
Sell 13 K USD
LAND RAYMOND J
Director
- 925
14 USD
12 years ago
Mar 19, 2012
Sell 12.1 K USD
LAND RAYMOND J
Director
- 1000
12.132 USD
12 years ago
Mar 19, 2012
Sell 17.9 K USD
LAND RAYMOND J
Director
- 1500
11.917 USD
14 years ago
Aug 23, 2010
Bought 5.04 K USD
Mrachek William
Vice President, Human Resource
+ 1000
5.0391 USD
14 years ago
Aug 23, 2010
Bought 20 K USD
QUINLAN KEVIN W
Chief Financial Officer
+ 4000
5 USD
16 years ago
Nov 07, 2008
Bought 5.2 K USD
QUINLAN KEVIN W
Chief Financial Officer
+ 1000
5.2 USD
16 years ago
Nov 06, 2008
Bought 5.34 K USD
QUINLAN KEVIN W
Chief Financial Officer
+ 1000
5.34 USD
16 years ago
Mar 19, 2008
Bought 7.47 K USD
QUINLAN KEVIN W
Chief Financial Officer
+ 900
8.3 USD
16 years ago
Mar 19, 2008
Bought 6.63 K USD
QUINLAN KEVIN W
Chief Financial Officer
+ 800
8.29 USD
16 years ago
Mar 19, 2008
Bought 1.66 K USD
QUINLAN KEVIN W
Chief Financial Officer
+ 200
8.28 USD
16 years ago
Mar 19, 2008
Bought 820 USD
QUINLAN KEVIN W
Chief Financial Officer
+ 100
8.2 USD
16 years ago
Mar 14, 2008
Sell 4.48 K USD
SHERWOOD CHARLES H
President & CEO
- 500
8.95 USD
16 years ago
Mar 14, 2008
Sell 1.79 K USD
SHERWOOD CHARLES H
President & CEO
- 200
8.97 USD
16 years ago
Mar 14, 2008
Sell 171 USD
SHERWOOD CHARLES H
President & CEO
- 19
8.98 USD
16 years ago
Mar 14, 2008
Sell 3.43 K USD
SHERWOOD CHARLES H
President & CEO
- 381
8.99 USD
16 years ago
Mar 14, 2008
Sell 3.6 K USD
SHERWOOD CHARLES H
President & CEO
- 400
9 USD
16 years ago
Mar 14, 2008
Sell 1.81 K USD
SHERWOOD CHARLES H
President & CEO
- 200
9.03 USD
16 years ago
Mar 14, 2008
Sell 3.62 K USD
SHERWOOD CHARLES H
President & CEO
- 400
9.06 USD
16 years ago
Mar 14, 2008
Sell 1.81 K USD
SHERWOOD CHARLES H
President & CEO
- 200
9.07 USD
16 years ago
Mar 14, 2008
Sell 1.82 K USD
SHERWOOD CHARLES H
President & CEO
- 200
9.08 USD
16 years ago
Mar 14, 2008
Sell 2.73 K USD
SHERWOOD CHARLES H
President & CEO
- 300
9.09 USD
16 years ago
Mar 14, 2008
Sell 1.83 K USD
SHERWOOD CHARLES H
President & CEO
- 200
9.15 USD
16 years ago
Mar 14, 2008
Sell 918 USD
SHERWOOD CHARLES H
President & CEO
- 100
9.18 USD
16 years ago
Mar 14, 2008
Sell 849 USD
SHERWOOD CHARLES H
President & CEO
- 100
8.49 USD
16 years ago
Mar 14, 2008
Sell 3.4 K USD
SHERWOOD CHARLES H
President & CEO
- 400
8.5 USD
16 years ago
Mar 14, 2008
Sell 9.36 K USD
SHERWOOD CHARLES H
President & CEO
- 1100
8.51 USD
7. News
New Strong Sell Stocks for November 11th AMRK, ANIK and ALG have been added to the Zacks Rank #5 (Strong Sell) List on November 11, 2024. zacks.com - 6 days ago
Anika Therapeutics, Inc. (ANIK) Q3 2024 Earnings Call Transcript Anika Therapeutics, Inc. (NASDAQ:ANIK ) Q3 2024 Earnings Conference Call October 31, 2024 8:30 AM ET Company Participants Matt Hall - Director, Corporate Development and IR Cheryl Blanchard - President and CEO Steve Griffin - EVP, CFO and Treasurer Conference Call Participants Jim Sidoti - Sidoti & Co. Mike Petusky - Barrington Research Operator Good morning, ladies and gentlemen, and welcome to Anika's Third Quarter Earnings Conference Call. [Operator Instructions]. seekingalpha.com - 2 weeks ago
Anika Therapeutics (ANIK) Reports Q3 Loss, Lags Revenue Estimates Anika Therapeutics (ANIK) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of $0.30. This compares to loss of $0.45 per share a year ago. zacks.com - 2 weeks ago
Anika Reports Third Quarter 2024 Financial Results Updating 2024 fiscal year guidance to reflect announced changes to business strategy, including the sale of Arthrosurface and planned divestiture of Parcus Medical, and U.S. OA Pain Management headwinds globenewswire.com - 2 weeks ago
Anika Announces Strategic Update of Business with Sale of Arthrosurface and Plan to Divest Parcus Medical Company to Focus on Profitable Hyaluronic Acid-Driven OA Pain Management and High Growth Regenerative Solutions Portfolio, Streamline Operations and Enhance Growth Profile Company to Focus on Profitable Hyaluronic Acid-Driven OA Pain Management and High Growth Regenerative Solutions Portfolio, Streamline Operations and Enhance Growth Profile globenewswire.com - 2 weeks ago
Anika Announces Third Quarter 2024 Results Conference Call Date BEDFORD, Mass., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, announced today that it will issue its third quarter 2024 financial results before the opening of the market on Thursday, October 31, 2024, followed by a conference call at 8:30 a.m. ET to discuss its results and business highlights. globenewswire.com - 1 month ago
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BEDFORD, Mass., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that on October 1, 2024, Anika granted non-statutory stock options (“Options”) covering an aggregate of 6,350 shares of common stock at a per share exercise price of $24.27, which equaled the closing price of common stock on the Nasdaq Global Select Market (“Closing Price”) on the grant date, to one newly hired non-executive employee. The grant was made pursuant to the Anika Therapeutics, Inc. 2021 Inducement Plan, as amended, was approved by the compensation committee of the board of directors pursuant to a delegation of authority by the board of directors, and, in accordance with Nasdaq Listing Rule 5635(c)(4), was made as a material inducement to the grantee's acceptance of employment with Anika as a component of the grantee's employment compensation. globenewswire.com - 1 month ago
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BEDFORD, Mass., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that on September 3, 2024, Anika granted non-statutory stock options (“Options”) covering an aggregate of 2,500 shares of common stock at a per share exercise price of $25.15, which equaled the closing price of common stock on the Nasdaq Global Select Market (“Closing Price”) on the grant date, to one newly hired non-executive employee. The grant was made pursuant to the Anika Therapeutics, Inc. 2021 Inducement Plan, as amended, was approved by the compensation committee of the board of directors pursuant to a delegation of authority by the board of directors, and, in accordance with Nasdaq Listing Rule 5635(c)(4), was made as a material inducement to the grantee's acceptance of employment with Anika as a component of the grantee's employment compensation. globenewswire.com - 2 months ago
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BEDFORD, Mass., Aug. 15, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that on August 1, 2024, Anika granted non-statutory stock options (“Options”) covering an aggregate of 8,850 shares of common stock at a per share exercise price of $26.29, which equaled the closing price of common stock on the Nasdaq Global Select Market (“Closing Price”) on the grant date, to two newly hired non-executive employees. The grants were made pursuant to the Anika Therapeutics, Inc. 2021 Inducement Plan, as amended, were approved by the compensation committee of the board of directors pursuant to a delegation of authority by the board of directors, and, in accordance with Nasdaq Listing Rule 5635(c)(4), were made as a material inducement to the grantee's acceptance of employment with Anika as a component of the grantee's employment compensation. globenewswire.com - 3 months ago
Anika Therapeutics, Inc (ANIK) Q2 2024 Earnings Call Transcript Anika Therapeutics, Inc (NASDAQ:ANIK ) Q2 2024 Earnings Call August 8, 2024 5:00 PM ET Company Participants Mark Namaroff - Vice President, Investor Relations Cheryl Blanchard - President and Chief Executive Officer Steve Griffin - Executive Vice President, Chief Financial Officer and Treasurer Conference Call Participants Jim Sidoti - Sidoti & Company Harrison Parsons - Stephens Mike Petusky - Barrington Research Operator Good afternoon, ladies and gentlemen, and welcome to Anika's Second Quarter 2024 Earnings Conference Call. [Operator Instructions] I will now turn the call over to Mark Namaroff, Vice President, Investor Relations, ESG and Corp. Communications. seekingalpha.com - 3 months ago
Anika Therapeutics (ANIK) Q2 Earnings Lag Estimates Anika Therapeutics (ANIK) came out with quarterly earnings of $0.17 per share, missing the Zacks Consensus Estimate of $0.23 per share. This compares to loss of $0.19 per share a year ago. zacks.com - 3 months ago
Anika Reports Second Quarter 2024 Financial Results Expanded Regenerative Solutions portfolio with full market release of the Integrity™  Implant System, a hyaluronic acid (HA)-based scaffold for rotator cuff and other tendon repairs, generating significant market demand globenewswire.com - 3 months ago
8. Profile Summary

Anika Therapeutics, Inc. ANIK

image
COUNTRY US
INDUSTRY Medical - Devices
MARKET CAP $ 253 M
Dividend Yield 0.00%
Description Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management product family consists of Monovisc, Orthovisc, Cingal, and Hyvisc that are indicated to provide pain relief from osteoarthritis conditions; and joint preservation and restoration product family comprise a portfolio of approximately 150 bone preserving joint technology products, a line of sports medicine soft tissue repair solutions, and orthopedic regenerative solutions products. The company's non-orthopedic product family include HA-based products for non-orthopedic applications, including adhesion barrier products, advanced wound care products, ophthalmic products, and ear, nose, and throat products. Anika Therapeutics, Inc. was founded in 1983 and is headquartered in Bedford, Massachusetts.
Contact 32 Wiggins Avenue, Bedford, MA, 01730 https://www.anikatherapeutics.com
IPO Date May 3, 1993
Employees 357
Officers Dr. Cheryl Renee Blanchard Ph.D. President, Chief Executive Officer & Director Ms. Lisa Funiciello Vice President of Human Resources Mr. Stephen D. Griffin Executive Vice President, Chief Financial Officer & Treasurer Mr. David Colleran J.D. Executive Vice President, General Counsel & Corporate Secretary Mr. Ben Joseph Vice President of Commercial & Corporate Development Ms. Anne Nunes Senior Vice President & Chief Operating Officer Mr. Mark Namaroff Vice President of Investor Relations, ESG & Corporate Communications Mr. James Chase Senior Vice President of International Sales & Marketing Mr. Ian W. McLeod Vice President & Chief Accounting Officer